Immunetrics specializes in creating predictive biological models that simulate drug targets and clinical trials. These models are designed to inform decisions at every stage of drug development, from preclinical targeting to FDA requests. The company serves pharmaceutical and biotechnology firms, providing them with tools to optimize trial designs, evaluate combination drug synergies, and identify target patient populations. Immunetrics operates in the healthcare and life sciences market, leveraging advanced mathematics, biology, and software engineering to build its models. The business model includes licensing their models for use in projects or within their Thales model development platform, which incorporates AI and machine learning to enhance model-building processes. Revenue is generated through licensing fees and consulting services, including clinical trial simulations and optimization.

Keywords: predictive models, drug development, clinical trials, biotechnology, pharmaceutical, AI, machine learning, healthcare, simulation, Thales platform.